BDBruno Diniz

Bruno Diniz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bruno Diniz has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recent Advances in Understanding and Managing Alzheimer's Disease: from Pathogenesis to Treatment

    by Rafael Leituga de Carvalho Cavalcante, Maurício Samartino, Larissa Abussafi Miranda, Jeniffer da Silva Alencar Mendes, Tatiana de Lima Tanaka, Felipe de Oliveira Silva, Lucas Monteiro Molina, Bruno Carvalho Diniz, Daniela Alves Dantas, Dhyana Ataide Ferraz Sarges, et al.

    Objective: The objective of this article is to conduct a comprehensive review of recent advances in understanding the pathogenesis of Alzheimer's disease (AD) and innovations in its management, emphasizing how these developments can inform more effective therapeutic strategies. Initially, this study explores contemporary findings related to the molecular and cellular mechanisms contributing to AD pathology, including the aggregation of beta-amyloid and tau, neural inflammation, synaptic dysfunction, as well as the impact of genetic and environmental factors. Theoretical Framework: Alzheimer's disease (AD) presents itself as a growing challenge for global public health, given its rising prevalence and the significant impact on the affected individuals, their families, and the healthcare systems. Method: A systematic review was conducted using major scientific databases to collect relevant articles on recent advances in the understanding and management of Alzheimer's disease, from pathogenesis to treatment. Specific keywords were used to identify studies addressing new findings and interdisciplinary therapeutic strategies. This enabled the synthesis of effective approaches and the identification of research gaps, supporting evidence-based clinical practices. Results and Discussion: Recent research has identified novel genetic markers linked to Alzheimer's disease, enhancing early diagnosis. Studies have also demonstrated the efficacy of integrated cognitive therapies in slowing disease progression. Additionally, new pharmacological treatments targeting amyloid plaques have shown promise in clinical trials. However, challenges in uniform treatment efficacy across diverse populations highlight the need for tailored therapeutic approaches.


  • Implantation of a second glaucoma drainage device

    by Brian A. Francis, Rodrigo A. B. Fernandes, Handan Akil, Vikas Chopra, Bruno Diniz, James Tan, Alex Huang

    To evaluate success rates in controlling intraocular pressure (IOP) after implantation of a second glaucoma drainage device (GDD) with a Baerveldt glaucoma implant in patients with refractory glaucoma, with a secondary aim of reducing the need for postoperative glaucoma medications.


  • Open Access

    An Innovative Surgical Technique for Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelium in Yucatan Mini Pigs: Preliminary Results

    by Rodrigo A. Brant Fernandes, Michael Janusz Koss, Paulo Falabella, Francisco Rosa Stefanini, Mauricio Maia, Bruno Diniz, Ramiro Ribeiro, Yuntao Hu, David Hinton, Dennis O. Clegg, et al.

    BACKGROUND AND OBJECTIVE: To develop a safe and efficient surgical procedure for subretinal implantation into porcine eyes of a human embryonic stem cell-derived retinal pigmented epithelium (hESC-RPE) monolayer seeded onto a Parylene-C scaffold. This implant is referred to as CPCB-RPE1. MATERIALS AND METHODS: Ultrathin Parylene-C scaffolds were seeded with hESC-RPE and surgically implanted into the subretinal space of Yucatan mini pigs (n = 8). The surgery consisted of pars plana vitrectomy, induction of a limited retinal detachment, and peripheral retinotomy for insertion of the monolayer using a novel tissue injector, followed by silicone oil tamponade injection, laser photocoagulation around the retinotomy site, and inferior iridectomy. Oral cyclosporine was administered from day 1 and during the entire follow-up period. Three months later, the animals were euthanized and the eyes and major organs were submitted for histological analysis. Adjacent sections underwent immunohistochemical analysis to detect human cells using anti-TRA-1-85 (human blood group antigen) antibody and DAPI antibodies. RESULTS: The cell monolayer was immunopositive for TRA-1-85 3 months after implantation and migration from the Parylene-C scaffold was not detected. One eye had a mild inflammatory reaction around the implant that was negative for human biomarkers. No intraocular or systemic tumors were detected. CONCLUSION: The hESC-RPE cells survived for 3 months in this animal model. The surgical procedure for subretinal implantation of CPCB-RPE1 is feasible and safe, without cell migration off the scaffold or development of ocular or systemic tumors. [ Ophthalmic Surg Lasers Imaging Retina . 2016;47:342–351.]